Epigenetic regulation of human telomerase reverse transcriptase promoter activity during cellular differentiation

Genes, Chromosomes & Cancer
Liang LiuT O Tollefsbol

Abstract

The human telomerase reverse transcriptase (TERT) gene is transcriptionally inactivated in most differentiated cells but is reactivated in the majority of cancer cells. To elucidate how TERT is inactivated during differentiation, we applied all-trans retinoic acid (ATRA) to induce the differentiation of human teratocarcinoma (HT) cells and human acute myeloid leukemia (HL60) cells. We first showed that TERT promoter activity decreased rapidly, which preceded a gradual loss of endogenous telomerase activity following ATRA induction. To elucidate the underlying mechanisms of the reduced TERT promoter activity during differentiation, we performed epigenetic studies on the TERT promoter and found a progressive histone hypoacetylation coupled with a gradual accumulation of methylated cytosines in the TERT promoter. We also observed that the TERT promoter was less methylated in pluripotent HT cells than in multipotent HL60 cells throughout a 12-day differentiation process. This origin-dependent epigenetic change was also confirmed in histone acetylation studies, indicating that the TERT promoter was more resistant to deacetylation in HT cells than in HL60 cells. Taken together, our results demonstrate synergistic involvement of DNA m...Continue Reading

References

Aug 1, 1990·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·C W Greider
May 31, 1990·Nature·C B HarleyC W Greider
Feb 1, 1994·Current Opinion in Genetics & Development·B Amati, H Land
Dec 30, 1999·Nature Genetics·F FuksT Kouzarides
Jul 13, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Meyerson
Mar 29, 2001·Proceedings of the National Academy of Sciences of the United States of America·D XuM Henriksson
Jun 12, 2001·Medical Hypotheses·T O Tollefsbol, L G Andrews
Aug 11, 2001·Science·W ReikJ Walter
Oct 24, 2001·Experimental Gerontology·J CampisiM Rubio
Feb 14, 2002·Critical Reviews in Oncology/hematology·Meaghan P GrangerJerry W Shay
Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·Isabelle GuilleretJean Benhattar
Sep 24, 2002·Journal of Cellular Biochemistry·Theresa M Geiman, Keith D Robertson
Jun 18, 2003·Biochemical and Biophysical Research Communications·Nadejda G LopatinaTrygve O Tollefsbol
Jul 3, 2003·Cell·Shiaw Yih Lin, Stephen J Elledge
Aug 5, 2003·Molecular and Cellular Biology·Isabel JacoMaría A Blasco

❮ Previous
Next ❯

Citations

Oct 28, 2008·Molecular Biotechnology·Sharla M O PhippsTrygve O Tollefsbol
Mar 10, 2009·Nucleic Acids Research·Shuwen WangJiyue Zhu
Apr 1, 2010·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Renjith MathewShuwen Wang
Feb 2, 2006·Genome Research·Marina BibikovaJian-Bing Fan
Mar 26, 2013·American Journal of Respiratory Cell and Molecular Biology·Tianju LiuSem H Phan
May 15, 2010·Future Oncology·Michelle F MaritzKaren L MacKenzie
Jun 14, 2005·Expert Opinion on Therapeutic Targets·Terace M Fletcher
Dec 17, 2009·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Carolina Oliveira GigekMarilia de Arruda Cardoso Smith
Jan 5, 2013·Mutation Research·Evelyn LamyVolker Mersch-Sundermann
Mar 3, 2012·Gene·Michael DanielTrygve O Tollefsbol
Dec 17, 2015·Cancer Genetics·Jiaying DengKuaile Zhao
Dec 1, 2006·Mechanisms of Ageing and Development·Wai-Leong TamBing Lim
Apr 10, 2009·International Journal of Cancer. Journal International Du Cancer·Yuanyuan LiTrygve O Tollefsbol
Jun 16, 2007·Journal of Cellular Biochemistry·Joel B BerletchTrygve O Tollefsbol
Jul 29, 2006·Development, Growth & Differentiation·Noelia AndolloJuan M Aréchaga
Apr 2, 2015·Omics : a Journal of Integrative Biology·Seher Karsli-CeppiogluDominique Bernard-Gallon
Jun 13, 2019·Cell Communication and Signaling : CCS·Meng-Meng JieXin-Zhe Li
May 18, 2010·Molecular and Cellular Biochemistry·Jose SalvaticoMark T Muller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.